Eleven Bio Inc (EBIO) 3.14 $EBIO Eleven Biother
Post# of 273254
Posted On: 09/22/2016 7:00:31 PM
Eleven Bio Inc (EBIO) 3.14 $EBIO
Eleven Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BusinessWire - Wed Sep 21, 3:01PM CDT
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), today reported that in connection with the appointment of each of Stephen Hurly as President and Chief Executive Officer, Arthur P. DeCillis, M.D., as Chief Medical Officer, Glen MacDonald, Ph.D., as Chief Scientific Officer and Gregory P. Adams, Ph.D., as Chief Development Officer, the Company entered into employment agreements with each of Mr. Hurly, Dr. DeCillis, Dr. MacDonald and Dr. Adams which provided for the grant of an inducement equity award outside the Company's 2014 Stock Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
EBIO: 3.14 (-0.36)
Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted Protein Therapeutics Oncology Company
BusinessWire - Wed Sep 21, 6:00AM CDT
---Proxinium(TM) being developed for late-stage squamous cell carcinoma of the head and neck with Phase 2 initiation planned for early 2017-
EBIO: 3.14 (-0.36)
Biotech Stocks on Investors' Radar -- Eleven Biotherapeutics, CytRx, Celldex Therapeutics, and ACADIA Pharma
PR Newswire - Wed Sep 14, 8:19AM CDT
Stock-Callers.com has uncovered research reports on the following Biotech companies: Eleven Biotherapeutics Inc. (NASDAQ: EBIO), CytRx Corp. (NASDAQ: CYTR), Celldex Therapeutics Inc. (NASDAQ: CLDX), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). On Monday, September 13, 2016, the iShares NASDAQ Biotechnology ETF (IBB) rose 3%, which was its best day since late June. The IBB, however, is still down 19% in the past year. Learn more about these stocks by downloading their comprehensive and free reports at: http://stock-callers.com/registration
ACAD: 34.98 (-0.64), EBIO: 3.14 (-0.36), CLDX: 3.72 (unch), CYTR: 0.58 (-0.01)
Eleven Biotherapeutics Completes Exclusive Licensing Deal for IL-6 Antagonist Antibody Technology, Including EBI-031
BusinessWire - Tue Aug 16, 6:30AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the effectiveness of the exclusive licensing deal with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche). Eleven has granted Roche an exclusive, worldwide license to develop and commercialize EBI-031 and all other IL-6 antagonist antibody technology owned by Eleven. EBI-031 is a humanized monoclonal antibody that potently binds interleukin-6 (IL-6) and inhibits all known forms of IL-6 cytokine signaling. EBI-031 is currently in development for the treatment of ocular diseases. Eleven is entitled to receive $30 million in payments from Roche, including a $7.5 million upfront payment in connection with the effectiveness of the license agreement, and a $22.5 million milestone payment based on the Investigational New Drug application (IND) for EBI-031 becoming effective.
EBIO: 3.14 (-0.36)
Eleven Biotherapeutics Reports Second Quarter 2016 Financial Results and Provides Strategic Update
BusinessWire - Fri Aug 12, 6:30AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the second quarter ended June 30, 2016 and provided a review of recent business highlights.
EBIO: 3.14 (-0.36)
Eleven Biotherapeutics (EBIO) Jumps: Stock Rises by 10.4%
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:00AM CDT
Eleven Biotherapeutics, Inc. (EBIO) was a big mover last session, as the company saw its shares rise over 10% on the day.
EBIO: 3.14 (-0.36), ANIP: 66.81 (+1.69)
Four Companies To Consider for Your Portfolio in August 2016
PR Newswire - Thu Jul 28, 11:45AM CDT
TechStockInsider.com Briefing: The Fed held its two-day meeting this week and after much deliberation, the decision has been made to leave rates where they are for right now. The guidance came after identifying that the current economic state is still relatively unstable while the outlook for the global economic unrest mainly rippling from Brexit have still some uncertainty. Despite this outlook on the economy, the decision actually has spurred interest in many stocks this morning with many "bottomed out" equities seeing price reversals including:
EVOK: 2.01 (+0.12), EBIO: 3.14 (-0.36), SPU: 9.91 (-0.05)
Biotech Ready for a Breakout
ACCESSWIRE - Thu Jul 28, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / July 28, 2016 / The Biotechnology sector is still struggling with a personal bear market, after dropping 40% from its high point in July 2015. While the overall market has strengthened and risen quite a bit from its lows, the biotechnology sector, as represented by IBB, an ETF tracking the Nasdaq Biotechnology Index, is still down 24% for the year. While the broader indexes have enjoyed some resurgence, the IBB has not been able to even come close to the 200 DMA level this year, and was 11% below it at the end of June.
EBIO: 3.14 (-0.36)
Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
PR Newswire - Mon Jun 20, 7:25AM CDT
On Friday, June 17, 2016, the NASDAQ Composite ended the trading session at 4,800.34, down 0.92%; the Dow Jones Industrial Average edged 0.33% lower, to finish at 17,675.16; and the S&P 500 closed at 2,071.22, down 0.33%. However, five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Relypsa Inc. (NASDAQ: RLYP), Galena Biopharma Inc. (NASDAQ: GALE), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free trade alerts at:
EBIO: 3.14 (-0.36), RLYP: 31.98 (-0.01), AMGN: 175.62 (+1.77), GALE: 0.37 (+0.01)
Apple and Hanesbrands fall, LinkedIn and Symantec climb
AP - Mon Jun 13, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
ARGS: 4.94 (-0.22), LNKD: 192.48 (+0.08), EBIO: 3.14 (-0.36), DUK: 82.51 (+0.61), HBI: 26.15 (+0.01), AAPL: 114.62 (+1.07), SYMC: 25.08 (unch)
Eleven Biotherapeutics Announces Signing of Exclusive License Agreement
BusinessWire - Mon Jun 13, 6:45AM CDT
--IND Submission for EBI-031 Announced Today
EBIO: 3.14 (-0.36)
Eleven Biotherapeutics Announces Investigational New Drug Application Submission to Initiate Clinical Trials of EBI-031 for Ocular Diseases
BusinessWire - Mon Jun 13, 6:30AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of EBI-031, a humanized monoclonal antibody that potently binds interleukin-6 (IL-6) and inhibits all known forms of IL-6 cytokine signaling, which may be effective for the treatment of ocular diseases such as diabetic macular edema and uveitis.
EBIO: 3.14 (-0.36)
Eleven Biotherapeutics Reports First Quarter 2016 Financial Results
BusinessWire - Thu May 05, 6:30AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the first quarter ended March 31, 2016 and provided a review of recent business highlights.
EBIO: 3.14 (-0.36)
Four Top Stocks to Watch on Wednesday May 4th 2016
ACCESSWIRE - Wed May 04, 11:03AM CDT
MIAMI, FL / ACCESSWIRE / May 4, 2016 / Tech Stock Insider is issuing a report on four stocks to watch. EBIO, LCLP, XGTI, and MJNA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks, subscribe to our newsletter at TechStockInsider.com.
EBIO: 3.14 (-0.36), XGTI: 0.30 (-0.02)
Genetic Stratification of Drug Response in IL-1 Implicated Eye Diseases
GlobeNewswire - Wed May 04, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, presented new data from post hoc analyses on the influence of Interleukin's IL-1 genetic patterns on response to isunakinra (EBI-005) in severe allergic conjunctivitis and severe dry eye study subjects. The data were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington.
EBIO: 3.14 (-0.36)
Eleven Biotherapeutics to Present Data at the ARVO 2016 Annual Meeting
BusinessWire - Fri Apr 29, 7:32AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that one oral presentation and three posters have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting taking place May 1-5, 2016, in Seattle, WA. The presentations include preclinical data for EBI-031, which is in development for diabetic macular edema and Phase 3 clinical data on isunakinra (EBI-005). Presentation abstracts can be found on the ARVO website at https://www.arvo.org/AM/Program/.
EBIO: 3.14 (-0.36)
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 8.96 (-0.03), EBIO: 3.14 (-0.36), PTCT: 10.94 (+0.50), PETX: 9.41 (+0.28), ARRY: 3.69 (+0.10)
Trending Stocks To Have On Your Watch-list Friday (4/22/16)
ACCESSWIRE - Fri Apr 22, 11:21AM CDT
MIAMI, FL / ACCESSWIRE / April 22, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. COOL, NEOT, EBIO, and ARTX have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
COOL: 3.34 (-0.01), EBIO: 3.14 (-0.36), ARTX: 3.01 (-0.12), NEOT: 1.25 (+0.11), MJCO: 5.00 (+0.05)
4 Trending Small Cap Stocks Making Big Moves Today
ACCESSWIRE - Fri Apr 22, 9:12AM CDT
NEW YORK, NY / ACCESSWIRE / April 22, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. EBIO, EXXI, SUNE and ATRS are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
EXXI: 0.13 (-0.01), EBIO: 3.14 (-0.36), SUNE: 0.34 (unch), ATRS: 1.66 (+0.05)
Penny Stocks to Watch on Thursday April 21
ACCESSWIRE - Thu Apr 21, 12:08PM CDT
MIAMI, FL / ACCESSWIRE / April 21, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. CBYL, EBIO, RJETQ, and AGHI have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, NASDAQ and NYSE subscribe to our newsletter at DailyStockReporter.com.
EBIO: 3.14 (-0.36), CBYL: 0.48 (+0.01)
Eleven Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BusinessWire - Wed Sep 21, 3:01PM CDT
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), today reported that in connection with the appointment of each of Stephen Hurly as President and Chief Executive Officer, Arthur P. DeCillis, M.D., as Chief Medical Officer, Glen MacDonald, Ph.D., as Chief Scientific Officer and Gregory P. Adams, Ph.D., as Chief Development Officer, the Company entered into employment agreements with each of Mr. Hurly, Dr. DeCillis, Dr. MacDonald and Dr. Adams which provided for the grant of an inducement equity award outside the Company's 2014 Stock Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
EBIO: 3.14 (-0.36)
Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted Protein Therapeutics Oncology Company
BusinessWire - Wed Sep 21, 6:00AM CDT
---Proxinium(TM) being developed for late-stage squamous cell carcinoma of the head and neck with Phase 2 initiation planned for early 2017-
EBIO: 3.14 (-0.36)
Biotech Stocks on Investors' Radar -- Eleven Biotherapeutics, CytRx, Celldex Therapeutics, and ACADIA Pharma
PR Newswire - Wed Sep 14, 8:19AM CDT
Stock-Callers.com has uncovered research reports on the following Biotech companies: Eleven Biotherapeutics Inc. (NASDAQ: EBIO), CytRx Corp. (NASDAQ: CYTR), Celldex Therapeutics Inc. (NASDAQ: CLDX), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). On Monday, September 13, 2016, the iShares NASDAQ Biotechnology ETF (IBB) rose 3%, which was its best day since late June. The IBB, however, is still down 19% in the past year. Learn more about these stocks by downloading their comprehensive and free reports at: http://stock-callers.com/registration
ACAD: 34.98 (-0.64), EBIO: 3.14 (-0.36), CLDX: 3.72 (unch), CYTR: 0.58 (-0.01)
Eleven Biotherapeutics Completes Exclusive Licensing Deal for IL-6 Antagonist Antibody Technology, Including EBI-031
BusinessWire - Tue Aug 16, 6:30AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the effectiveness of the exclusive licensing deal with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche). Eleven has granted Roche an exclusive, worldwide license to develop and commercialize EBI-031 and all other IL-6 antagonist antibody technology owned by Eleven. EBI-031 is a humanized monoclonal antibody that potently binds interleukin-6 (IL-6) and inhibits all known forms of IL-6 cytokine signaling. EBI-031 is currently in development for the treatment of ocular diseases. Eleven is entitled to receive $30 million in payments from Roche, including a $7.5 million upfront payment in connection with the effectiveness of the license agreement, and a $22.5 million milestone payment based on the Investigational New Drug application (IND) for EBI-031 becoming effective.
EBIO: 3.14 (-0.36)
Eleven Biotherapeutics Reports Second Quarter 2016 Financial Results and Provides Strategic Update
BusinessWire - Fri Aug 12, 6:30AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the second quarter ended June 30, 2016 and provided a review of recent business highlights.
EBIO: 3.14 (-0.36)
Eleven Biotherapeutics (EBIO) Jumps: Stock Rises by 10.4%
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:00AM CDT
Eleven Biotherapeutics, Inc. (EBIO) was a big mover last session, as the company saw its shares rise over 10% on the day.
EBIO: 3.14 (-0.36), ANIP: 66.81 (+1.69)
Four Companies To Consider for Your Portfolio in August 2016
PR Newswire - Thu Jul 28, 11:45AM CDT
TechStockInsider.com Briefing: The Fed held its two-day meeting this week and after much deliberation, the decision has been made to leave rates where they are for right now. The guidance came after identifying that the current economic state is still relatively unstable while the outlook for the global economic unrest mainly rippling from Brexit have still some uncertainty. Despite this outlook on the economy, the decision actually has spurred interest in many stocks this morning with many "bottomed out" equities seeing price reversals including:
EVOK: 2.01 (+0.12), EBIO: 3.14 (-0.36), SPU: 9.91 (-0.05)
Biotech Ready for a Breakout
ACCESSWIRE - Thu Jul 28, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / July 28, 2016 / The Biotechnology sector is still struggling with a personal bear market, after dropping 40% from its high point in July 2015. While the overall market has strengthened and risen quite a bit from its lows, the biotechnology sector, as represented by IBB, an ETF tracking the Nasdaq Biotechnology Index, is still down 24% for the year. While the broader indexes have enjoyed some resurgence, the IBB has not been able to even come close to the 200 DMA level this year, and was 11% below it at the end of June.
EBIO: 3.14 (-0.36)
Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
PR Newswire - Mon Jun 20, 7:25AM CDT
On Friday, June 17, 2016, the NASDAQ Composite ended the trading session at 4,800.34, down 0.92%; the Dow Jones Industrial Average edged 0.33% lower, to finish at 17,675.16; and the S&P 500 closed at 2,071.22, down 0.33%. However, five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Relypsa Inc. (NASDAQ: RLYP), Galena Biopharma Inc. (NASDAQ: GALE), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free trade alerts at:
EBIO: 3.14 (-0.36), RLYP: 31.98 (-0.01), AMGN: 175.62 (+1.77), GALE: 0.37 (+0.01)
Apple and Hanesbrands fall, LinkedIn and Symantec climb
AP - Mon Jun 13, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
ARGS: 4.94 (-0.22), LNKD: 192.48 (+0.08), EBIO: 3.14 (-0.36), DUK: 82.51 (+0.61), HBI: 26.15 (+0.01), AAPL: 114.62 (+1.07), SYMC: 25.08 (unch)
Eleven Biotherapeutics Announces Signing of Exclusive License Agreement
BusinessWire - Mon Jun 13, 6:45AM CDT
--IND Submission for EBI-031 Announced Today
EBIO: 3.14 (-0.36)
Eleven Biotherapeutics Announces Investigational New Drug Application Submission to Initiate Clinical Trials of EBI-031 for Ocular Diseases
BusinessWire - Mon Jun 13, 6:30AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of EBI-031, a humanized monoclonal antibody that potently binds interleukin-6 (IL-6) and inhibits all known forms of IL-6 cytokine signaling, which may be effective for the treatment of ocular diseases such as diabetic macular edema and uveitis.
EBIO: 3.14 (-0.36)
Eleven Biotherapeutics Reports First Quarter 2016 Financial Results
BusinessWire - Thu May 05, 6:30AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the first quarter ended March 31, 2016 and provided a review of recent business highlights.
EBIO: 3.14 (-0.36)
Four Top Stocks to Watch on Wednesday May 4th 2016
ACCESSWIRE - Wed May 04, 11:03AM CDT
MIAMI, FL / ACCESSWIRE / May 4, 2016 / Tech Stock Insider is issuing a report on four stocks to watch. EBIO, LCLP, XGTI, and MJNA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks, subscribe to our newsletter at TechStockInsider.com.
EBIO: 3.14 (-0.36), XGTI: 0.30 (-0.02)
Genetic Stratification of Drug Response in IL-1 Implicated Eye Diseases
GlobeNewswire - Wed May 04, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, presented new data from post hoc analyses on the influence of Interleukin's IL-1 genetic patterns on response to isunakinra (EBI-005) in severe allergic conjunctivitis and severe dry eye study subjects. The data were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington.
EBIO: 3.14 (-0.36)
Eleven Biotherapeutics to Present Data at the ARVO 2016 Annual Meeting
BusinessWire - Fri Apr 29, 7:32AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that one oral presentation and three posters have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting taking place May 1-5, 2016, in Seattle, WA. The presentations include preclinical data for EBI-031, which is in development for diabetic macular edema and Phase 3 clinical data on isunakinra (EBI-005). Presentation abstracts can be found on the ARVO website at https://www.arvo.org/AM/Program/.
EBIO: 3.14 (-0.36)
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 8.96 (-0.03), EBIO: 3.14 (-0.36), PTCT: 10.94 (+0.50), PETX: 9.41 (+0.28), ARRY: 3.69 (+0.10)
Trending Stocks To Have On Your Watch-list Friday (4/22/16)
ACCESSWIRE - Fri Apr 22, 11:21AM CDT
MIAMI, FL / ACCESSWIRE / April 22, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. COOL, NEOT, EBIO, and ARTX have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
COOL: 3.34 (-0.01), EBIO: 3.14 (-0.36), ARTX: 3.01 (-0.12), NEOT: 1.25 (+0.11), MJCO: 5.00 (+0.05)
4 Trending Small Cap Stocks Making Big Moves Today
ACCESSWIRE - Fri Apr 22, 9:12AM CDT
NEW YORK, NY / ACCESSWIRE / April 22, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. EBIO, EXXI, SUNE and ATRS are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
EXXI: 0.13 (-0.01), EBIO: 3.14 (-0.36), SUNE: 0.34 (unch), ATRS: 1.66 (+0.05)
Penny Stocks to Watch on Thursday April 21
ACCESSWIRE - Thu Apr 21, 12:08PM CDT
MIAMI, FL / ACCESSWIRE / April 21, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. CBYL, EBIO, RJETQ, and AGHI have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, NASDAQ and NYSE subscribe to our newsletter at DailyStockReporter.com.
EBIO: 3.14 (-0.36), CBYL: 0.48 (+0.01)
(0)
(0)Scroll down for more posts ▼